πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10100018

Amide derivatives as lysophosphatidic acid receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10081626

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10064845

Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antag

Cumberland Pharmaceuticals Inc. Β· Granted Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10066017

Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagon

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10059744

Ξ±4Ξ²7 thioether peptide dimer antagonists

Protagonist Therapeutics, Inc. Β· Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10059771

Methods for treating nasal polyposis by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10047122

Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10035833

Vascular endothelial growth factor antagonists and methods of making

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10011588

1,2-substituted cyclopentanes as orexin receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10011647

IL-33 antagonists and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10005771

Bicyclic derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

Almirall, S.A. Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10000456

Polycyclic compounds as lysophosphatidic acid receptor antagonists

AMIRA PHARMACEUTICALS, INC. Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10000477

Dopamine D3 receptor antagonist compounds

Indivior UK Limited Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9987253

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders,

Jenrin Discovery, LLC Β· Granted Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9980936

BH4 antagonists and methods related thereto

The Board of Regents of the University of Texas System Β· Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9975875

Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agon

Theravance Respiratory Company, LLC Β· Granted Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9974742

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. Β· Granted Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951010

Compounds as CRTH2 antagonist and uses thereof

SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9951017

S1P3 antagonists

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9926272

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914763

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9896509

Use of antagonists of the interaction between HIV GP120 and Ξ±4Ξ²7 integrin

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9896502

Antagonist antibodies directed against calcitonin gene-related peptide and methods using s

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890210

Antagonist antibodies directed against calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted